홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

클로드로닉산

Clodronate

HCID 25419
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
10596-23-3
표준 SMILES
O=P(O)(O)C(Cl)(Cl)P(=O)(O)O
InChIKey
ACSIXWWBWUQEHA-UHFFFAOYSA-N
분자식
CH4Cl2O6P2
평균 분자량
244.89 g/mol
단동위원소 질량
243.8860172

개요

Clodronic acid is an organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases. It has a role as an antineoplastic agent and a bone density conservation agent. It is an organochlorine compound, a one-carbon compound and a 1,1-bis(phosphonic acid). It is a conjugate acid of a clondronate(2-).

이름 및 식별자

우선 이름
Clodronate
IUPAC
[dichloro(phosphono)methyl]phosphonic acid
현지명
클로드로닉산
영어명
Clodronic acid
분자식
CH4Cl2O6P2
분자량
244.89

이름 및 동의어

Clodronic Acid10596-23-3Clodronate(Dichloromethylene)diphosphonic acidAcido clodronicoAcide clodroniqueAcidum clodronicumClodronsaeure[dichloro(phosphono)methyl]phosphonic acidDichloromethylidene diphosphonate(Dichloromethylene)bisphosphonic acidDichloromethanediphosphonic acid
이름 더 보기
클로드로닉산diphosphonic acidClodronicDichloromethylenebisphosphonic acid(Dichloromethylene)bis(phosphonic acid)ARC-69931Aids071014Aids-071014Clodronate AcidClodronic acid 18O3
Phosphonic acid, (dichloromethylene)bis-ClasteonLoron(Dichloro-phosphono-methyl)-phosphonic aciddichloromethylene-1,1-diphosphonic aciddichloromethylene-1,1-bisphosphonic acidDTXSID8046959Acid, Clodronic

데이터베이스 식별자

CAS
10596-23-3

물성

구조 계산 물성

XLogP
-2.1
극성 표면적
115 Ų
수소 결합 공여자 수
4
수소 결합 수용자 수
6
회전 가능 결합 수
2
무거운 원자 수
11
형식 전하
0
복잡도
211

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

LogP-2.4
Solubility7.47e+00 g/L
Animal Drugs · 2건

FDA approved animal drugs -> Active ingredient

Pharmaceuticals -> UK Veterinary Medicines Directorate List

Melting Point250 °C
Physical DescriptionSolid

물리화학적 성질

녹는점
249 · 249-251°
끓는 점
474.7 · 474.7±55.0 °C(Predicted)
밀도
2.306 · 2.306±0.06 g/cm3(Predicted)
저장 조건
2 · under inert gas (nitrogen or Argon) at 2-8°C
물리적 상태
Solid
산도 계수 (pKa)
0.75 · 0.75±0.10(Predicted)
색상
Off-white to light yellow
InChI
InChI=1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9)

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

독성 정보

Health EffectsDecreases in serum calcium following substantial overdosage may be expected in some patients.
Exposure RoutesOral, Intravenous. After oral administration, absorption is estimated at 1–3% of the ingested dose because of the low uptake from the gastrointestinal tract.
Toxicity Summary · 1건

The bisphosphonate group binds strongly to the bone mineral, hydroxyapatite. This explains the specific pharmacological action of these compounds on mineralized tissues, especially bone. The exact mechanism of action of clodronate is not known, however it is known that it does not inhibit protein isoprenylation but can be metabolized intracellularly to a &beta;-&gamma;-methylene (AppCp-type) analog of ATP (AppCCl2p), which is cytotoxic to macrophages in vitro. Inhibition of the ADP/ATP translocase by the metabolite AppCCl2p is a likely route by which clodronate causes osteoclast apoptosis and inhibits bone resorption. Recently, the slime mold <i>Dictyostelium discoideum</i> was shown to take up bisphosphonates by pinocytosis. In these cells, clodronate, but not other pharmacologically active bisphosphonates, was incorporated into adenine nucleotides, which could potentially explain why this bisphosphonate sometimes seems to act differently than the other bisphosphonates. Clodronate, like all biphosphonates, also binds protein-tyrosine-phosphatase.

Signs and SymptomsSigns and symptoms of hypocalcemia also may occur in some of these patients.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 4건

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Clodronic acid

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

안전 데이터

신호 어

화학 및 산업

약리 정보

ATC Code · 3건

M05BA02

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein BindingClodronic acid is 36% protein bound in plasma.
Pharmacodynamics · 1건

Clodronic acid is a first generation bisphosphonate that inhibits osteoclast mediated bone resorption. It has a wide therapeutic index as a large overdose is required for significant toxicity and a long duration of action due to the slow release from bone. Patients should be counselled regarding the risk of hypocalcemia, hypovolemia, renal insufficiency, transient hyperphosphatemia, and transient hyperparathyroidism.

Mechanism of Action · 1건

Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis. Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act. Osteoclasts mediate resorption of bone. When osteoclasts bind to bone they form podosomes, ring structures of F-actin. Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption. First generation bisphosphonates closely mimic the structure of pyrophosphate, which can be incorporated into ATP anologues that cannot be hydrolyzed, disrupting all ATP mediated actions of osteoclasts.

Biological Half-LifeThe mean plasma half life of clodronate is 5.6h.
Metabolism/Metabolites · 2건

Clodronate is not metabolized in humans.

Clodronate is not metabolized in humans. It can be metabolized intracellularly to a beta-gamma-methylene (AppCp-type) analog of ATP (AppCCl2p), which is cytotoxic to macrophages in vitro. Half Life: Approximately 13 hours.

MeSH Pharmacological ClassificationAgents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.

관련 반응

7건
반응 기록 만들기
HRID 431286 반응식
HRID 431286반응물로
HRID 1157346 반응식
HRID 1157346생성물로
HRID 1181911 반응식
HRID 1181911생성물로
HRID 1182403 반응식
HRID 1182403반응물로
HRID 1602952 반응식
HRID 1602952반응물로
HRID 1602975 반응식
HRID 1602975반응물로
HRID 1817514 반응식
HRID 1817514생성물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
PubChem CID
25419
DTXSID
DTXSID8046959
ChEMBL
CHEMBL12318
ChEBI
CHEBI:110423
UNII
0813BZ6866
EC Number
234-212-1
Nikkaji
J10.448E
InChIKey
ACSIXWWBWUQEHA-UHFFFAOYSA-N
SMILES
C(P(=O)(O)O)(P(=O)(O)O)(Cl)Cl
Danger
유해·위험 문구
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드 H290
Absorption, Distribution and Excretion · 3건

Oral clodronic acid has a bioavailability of 1-2%. A 200mg intravenous dose reaches a Cmax of 16.1mg/L with an AUC of 44.2mg\*h/L. A 200mg intramuscular dose reaches a Cmax of 12.8mg/L with an AUC of 47.5mg\*h/L. Further pharmacokinetic data for clodronic acid are not readily available.

Clodronate is eliminated unchanged in the urine.

The renal clearance of clodronate is approximately 90mL/min.

Cellular LocationsCytoplasm

용도 및 제조

Uses · 2건

Use (kg; approx.) in Germany (2009): >500

A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. For the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors.

응용 분야

용도Clodronic Acid is a bisphosphonate that can be used in the treatment of osteoporosis. Its ATP-analogs can inhibit cell signaling pathways.

상·하류 제품 정보

상류 원료

메틸렌디브로마이드
추가 설명 · 1건

정의ChEBI: An organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the trea ment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases.